2-AI Stats & Data

— Pharmacology: In vitro profiling shows 2‑aminoindane acts as a monoamine transporter substrate with higher potency at NET and DAT than at SERT, and it binds α2‑adrenergic receptors at low‑to‑mid‑nanomolar Ki, consistent with reports of peripheral vasoconstriction, piloerection and mild analgesia. This profile distinguishes it from serotonergic aminoindanes such as MDAI. — Dose uncertainty: Formal human dose‑finding data are lacking; community reports vary widely, from inactive at 10–20 mg oral to clear stimulation at 50–100+ mg, with rectal administration increasing intensity. Start low, especially with new batches. — Duration and redosing: The active phase is short, but residual stimulation can prolong into insomnia; repeated redoses compress sleep and may precipitate anxiety or paranoid thoughts. Build a clear ‘no‑redose after X hours’ rule before starting. — Cardiovascular risk: Expect elevations in BP/HR; those with hypertension, arrhythmia, or other cardiovascular disease should avoid. Seek urgent care for chest pain, severe headache, confusion, or temperature >38.5 °C. — ROA risks: Intranasal use is notably painful and damaging to mucosa; use isotonic saline rinses if mistakenly insufflated. Rectal use should employ sterile water, body‑temperature isotonic solution and clean syringes (no needles), and precise volumetric dosing; avoid if there is rectal bleeding or inflammation. — Comedown/sleep: Prefer non‑pharmacologic sleep hygiene first (dark room, magnesium glycinate, hydration). If a sedative is used, avoid alcohol co‑use and do not stack multiple depressants. — Drug checking: Aminoindanes/NPS are frequently mis‑sold; confirm identity with multi‑reagent testing and, ideally, lab analysis (GC/MS/FTIR). Reagent color reactions for 2‑AI are inconsistent across batches; treat color tests as presumptive only. — Tolerance: Acute tolerance rises quickly during a session and decays over about a week; spacing sessions ≥7 days is prudent.